Regulatory Filing for Teduglutide

MFN Publicerad: 13 Sep 2024 11:30

Newbury has through one of its partners initiated a DCP filing for Teduglutide on Day-1 following the expiry of Data Exclusivity.

Teduglutide has been developed for the treatment of short bowel syndrome (SBS), a rare condition that impairs the small intestine’s ability to properly absorb nutrients and fluids.

This submission presents a first-to-market opportunity for Newbury, emphasizing our commitment to addressing unmet medical needs in the rare disease segment. Launch is anticipated to take place in 2026.

Teduglutide achieved a turnover of approximately 10 M€ in the Nordics during the past 12 months, according to DLMI (MAT August 2024).

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [email protected] or +46 (0) 40 200 250.

Börskollen

För dig med koll på börsen

Pressmeddelande

Regulatory Filing for Teduglutide

Bifogade filer

Nyheter om Newbury Pharmaceuticals

Läses av andra just nu

Om aktien Newbury Pharmaceuticals

Senaste nytt